Kane Biotech Inc. (CVE:KNE – Get Free Report) shot up 20% during mid-day trading on Friday . The company traded as high as C$0.03 and last traded at C$0.03. Approximately 102,100 shares traded hands during trading, a decline of 42% from the average daily volume of 175,952 shares. The stock had previously closed at C$0.03.
Kane Biotech Stock Performance
The firm has a market cap of C$6.15 million, a P/E ratio of -3.00 and a beta of 1.05. The company has a current ratio of 0.61, a quick ratio of 0.39 and a debt-to-equity ratio of -197.52. The company’s 50-day moving average is C$0.03 and its two-hundred day moving average is C$0.03.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Stories
- Five stocks we like better than Kane Biotech
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
